# Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection

> **NCT02707900** · PHASE1 · TERMINATED · sponsor: **University of North Carolina, Chapel Hill** · enrollment: 6 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Vorinostat
- **BIOLOGICAL:** AGS-004

## Key facts

- **NCT ID:** NCT02707900
- **Lead sponsor:** University of North Carolina, Chapel Hill
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03
- **Primary completion:** 2018-07-11
- **Final completion:** 2018-07-11
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.
- **Last updated:** 2019-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02707900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02707900, "Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02707900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*